Novo Nordisk Share Price Dips After Drug Trial Novo Nordisk's older oral semaglutide failed late-stage trials to slow Alzheimer's cognitive decline. Drug trial aimed to slow cognitive decline in Alzheimer's patients. Company's share price dropped 10% after trial results. Pharmaceuticals | Stocks | Alzheimer's Denmark 1 month ago